Visceral adiposity index and risks of cardiovascular events and mortality in prevalent hemodialysis patients

Hung-Yuan Chen, Yen-Ling Chiu, Yi-Fang Chuang, Shih-Ping Hsu, Mei-Fen Pai, Ju-Yeh Yang, Yu-Sen Peng, Hung-Yuan Chen, Yen-Ling Chiu, Yi-Fang Chuang, Shih-Ping Hsu, Mei-Fen Pai, Ju-Yeh Yang, Yu-Sen Peng

Abstract

Background: The visceral adiposity index (VAI) is a newly-derived measure of visceral adiposity with well-validated predictive power for cardiovascular (CV) outcomes in the general population. However, this predictability has not been investigated in hemodialysis patients, and whether VAI is superior to waist circumference (WC) and waist-to-height ratio (WHtR) in predicting CV outcomes and survival in hemodialysis patients remains unknown.

Methods: We performed a prospective study including 464 prevalent hemodialysis patients. The composite outcome was the occurrence of death and CV events during follow-up. Using multivariate Cox regression analysis, VAI, WC and WHtR were tested for the predictive power of outcomes. To evaluate the predictive performance of the VAI, WC and WHtR, time-dependent receiver operating characteristic curve (ROC) analysis was performed.

Results: VAI, WC and WHtR positively correlated with each other. Patients with a higher VAI (tertile 3 vs. tertile 1, adjusted hazard ratio (HR), 1.65; 95% confidence interval (CI), 1.12-2.42; tertile 2 vs. tertile 1, adjusted HR, 1.52; 95% CI, 1.1-2.18) had more composite outcomes. VAI had a similar predictive power of all-cause mortality to WC and WHtR, but superior predictive power of composite and CV outcomes to WC when analyzed by a stepwise forward likelihood ratio test. In time-dependent ROC analysis, VAI, WC and WHtR showed similar predictive performance for outcomes.

Conclusion: VAI is an optimal method to measure visceral adiposity to assess long-term CV outcomes and all-cause mortality in prevalent hemodialysis patients. VAI may provide a superior predictive power of CV outcomes to WC and WHtR.

Trial registration: ClinicalTrials.gov NCT01457625.

Figures

Figure 1
Figure 1
Relationship between visceral adiposity index (VAI) tertiles and all-cause mortality in hemodialysis patients with different nutritional status. The VAI predicted all-cause mortality in patients with a better nutritional status (GNRI ≥ 103.6) but not in those with a worse nutritional status (GNRI < 103.6). Analysis were adjusted for gender, age, hemodialysis vintage, presence of diabetes, hypertension and concurrent cardiovascular disease, hemoglobin, intact parathyroid hormone, high sensitive C-reactive protein and calcium phosphate product.

References

    1. DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, Poehlman ET. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001;24(5):925–932. doi: 10.2337/diacare.24.5.925.
    1. Chen HY, Lin CC, Chiu YL, Hsu SP, Pai MF, Yang JY, Peng YS. Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients. PLoS One. 2012;7(7):e38415. doi: 10.1371/journal.pone.0038415.
    1. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P, Lindholm B, Carrero JJ. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant. 2010;25(2):562–568. doi: 10.1093/ndt/gfp492.
    1. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–1159. doi: 10.1001/2012.jama.11132.
    1. Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, Maruyama Y, Odamaki M. Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant. 2011;26(6):1967–1976. doi: 10.1093/ndt/gfq652.
    1. Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, Stenvinkel P, Lindholm B. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr. 2007;86(3):633–638.
    1. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjonneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105–2120. doi: 10.1056/NEJMoa0801891.
    1. Zoccali C, Torino C, Tripepi G, Mallamaci F. Assessment of obesity in chronic kidney disease: what is the best measure? Curr Opin Nephrol Hypertens. 2012;21(6):641–646. doi: 10.1097/MNH.0b013e328358a02b.
    1. Evans PD, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3. PLoS One. 2012;7(4):e34699. doi: 10.1371/journal.pone.0034699.
    1. Postorino M, Marino C, Tripepi G, Zoccali C, Group CW. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol. 2009;53(15):1265–1272. doi: 10.1016/j.jacc.2008.12.040.
    1. Sanches FM, Avesani CM, Kamimura MA, Lemos MM, Axelsson J, Vasselai P, Draibe SA, Cuppari L. Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis. 2008;52(1):66–73. doi: 10.1053/j.ajkd.2008.02.004.
    1. Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, Wannamethee SG, Lawlor DA. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr. 2010;91(3):547–556. doi: 10.3945/ajcn.2009.28757.
    1. Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A. Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. Am J Clin Nutr. 1998;67(1):44–49.
    1. Lamacchia O, Pinnelli S, Camarchio D, Fariello S, Gesualdo L, Stallone G, Cignarelli M. Waist-to-height ratio is the best anthropometric index in association with adverse cardiorenal outcomes in type 2 diabetes mellitus patients. Am J Nephrol. 2009;29(6):615–619. doi: 10.1159/000194454.
    1. Postorino M, Marino C, Tripepi G, Zoccali C, Group CW. Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney Int. 2011;79(7):765–772. doi: 10.1038/ki.2010.493.
    1. Zoccali C, Postorino M, Marino C, Pizzini P, Cutrupi S, Tripepi G, Group CW. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med. 2011;269(2):172–181. doi: 10.1111/j.1365-2796.2010.02288.x.
    1. Lin HH, Lee JK, Yang CY, Lien YC, Huang JW, Wu CK. Accumulation of epicardial fat rather than visceral fat is an independent risk factor for left ventricular diastolic dysfunction in patients undergoing peritoneal dialysis. Cardiovasc Diabetol. 2013;12:127. doi: 10.1186/1475-2840-12-127.
    1. Pellicano R, Strauss BJ, Polkinghorne KR, Kerr PG. Longitudinal body composition changes due to dialysis. Clin J Am Soc Nephrol. 2011;6(7):1668–1675. doi: 10.2215/CJN.06790810.
    1. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study G. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–922. doi: 10.2337/dc09-1825.
    1. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Charalampidis P, Livadas S, Kollias A, Sabico SL, Chrousos GP. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur J Clin Investig. 2013;43(2):183–189. doi: 10.1111/eci.12030.
    1. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011;10:183. doi: 10.1186/1476-511X-10-183.
    1. Mohammadreza B, Farzad H, Davoud K, Fereidoun AF. Prognostic significance of the complex “Visceral Adiposity Index” vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012;11:20. doi: 10.1186/1475-2840-11-20.
    1. Chen HY, Chiu YL, Chuang YF, Hsu SP, Pai MF, Lai CF, Yang JY, Peng YS, Tsai TJ, Wu KD. Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2010;56(4):720–727. doi: 10.1053/j.ajkd.2010.06.015.
    1. Chiu YL, Chen HY, Chuang YF, Hsu SP, Lai CF, Pai MF, Yang SY, Peng YS. Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrol Dial Transplant. 2008;23(11):3685–3689. doi: 10.1093/ndt/gfn303.
    1. Chen HY, Chiu YL, Hsu SP, Pai MF, Lai CF, Peng YS, Kao TW, Hung KY, Tsai TJ, Wu KD. Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. Eur J Endocrinol. 2009;160(5):777–783. doi: 10.1530/EJE-08-0813.
    1. Chen HY, Chiu YL, Hsu SP, Pai MF, Lai CF, Yang JY, Peng YS, Tsai TJ, Wu KD. Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a potential mediator of high overall mortality. QJM. 2010;103(11):837–846. doi: 10.1093/qjmed/hcq036.
    1. Lai CF, Liao CH, Pai MF, Chu FY, Hsu SP, Chen HY, Yang JY, Chiu YL, Peng YS, Chang SC, Hung KY, Tsai TJ, Wu KD. Nasal carriage of methicillin-resistant Staphylococcus aureus is associated with higher all-cause mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(1):167–174. doi: 10.2215/CJN.06270710.
    1. Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S, Kumagai H. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr. 2008;87(1):106–113.
    1. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81(3):543–554.
    1. Miyamoto T, Rashid Qureshi A, Heimburger O, Barany P, Carrero K, Sjoberg B, Lindholm B, Stenvinkel P, Carrero JJ. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol. 2011;6(12):2785–2791. doi: 10.2215/CJN.02320311.
    1. Carvalho LK, Barreto Silva MI, da Silva Vale B, Bregman R, Martucci RB, Carrero JJ, Avesani CM. Annual variation in body fat is associated with systemic inflammation in chronic kidney disease patients Stages 3 and 4: a longitudinal study. Nephrol Dial Transplant. 2012;27(4):1423–1428. doi: 10.1093/ndt/gfr450.
    1. Cordeiro AC, Qureshi AR, Lindholm B, Amparo FC, Tito-Paladino-Filho A, Perini M, Lourenco FS, Pinto IM, Amodeo C, Carrero JJ. Visceral fat and coronary artery calcification in patients with chronic kidney disease. Nephrol Dial Transplant. 2013;28(Suppl 4):iv152–iv159. doi: 10.1093/ndt/gft250.
    1. Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity. 2013;21(8):1690–1694. doi: 10.1002/oby.20096.
    1. Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab. 2012;97(8):2907–2915. doi: 10.1210/jc.2012-1518.
    1. Mazzuca E, Battaglia S, Marrone O, Marotta AM, Castrogiovanni A, Esquinas C, Barcelo A, Barbe F, Bonsignore MR. Gender-specific anthropometric markers of adiposity, metabolic syndrome and visceral adiposity index (VAI) in patients with obstructive sleep apnea. J Sleep Res. 2014;23(1):13–21. doi: 10.1111/jsr.12088.
    1. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab. 2000;278(5):E941–E948.
    1. Taksali SE, Caprio S, Dziura J, Dufour S, Cali AM, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes. 2008;57(2):367–371. doi: 10.2337/db07-0932.
    1. Velludo CM, Kamimura MA, Sanches FM, Lemos MM, Canziani ME, Pupim LB, Draibe SA, Cuppari L. Prospective evaluation of waist circumference and visceral adipose tissue in patients with chronic kidney disease. Am J Nephrol. 2010;31(2):104–109. doi: 10.1159/000259896.
    1. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B, Bergstrom J. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002;13(Suppl 1):S28–S36.
    1. Huang JW, Yang CY, Wu HY, Liu KL, Su CT, Wu CK, Lee JK, Chiang CK, Cheng HT, Lien YC, Hung KY. Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients. Cardiovasc Diabetol. 2013;12:86. doi: 10.1186/1475-2840-12-86.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する